Verrica Pharmaceuticals Inc. priced its IPO of 5 million common shares at $15 apiece to raise gross proceeds of about $75 million.

The company has also granted the underwriters an option to buy up to an additional 750,000 shares.

Verrica said the shares are scheduled to start trading on the Nasdaq Global Market on June 15 under the ticker symbol VRCA.

The offering is expected to close June 19.

Bank of America Merrill Lynch, Jefferies and Cowen are serving as joint book-running managers for the offering.